Open Access

Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines

  • Authors:
    • Kan Omi
    • Yoichi Matsuo
    • Goro Ueda
    • Yoshinaga Aoyama
    • Tomokatsu Kato
    • Yuichi Hayashi
    • Hiroyuki Imafuji
    • Kenta Saito
    • Ken Tsuboi
    • Mamoru Morimoto
    • Ryo Ogawa
    • Hiroki Takahashi
    • Shuji Takiguchi
  • View Affiliations

  • Published online on: March 9, 2021     https://doi.org/10.3892/or.2021.8006
  • Article Number: 55
  • Copyright: © Omi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic cancer (PaCa) is one of the most aggressive types of cancer. Thus, the development of new and more effective therapies is urgently required. Escin, a pentacyclic triterpenoid from the horse chestnut, has been reported to exhibit antitumor potential by reducing cell proliferation and blocking the nuclear factor‑κB (NF‑κB) signaling pathway in several types of cancer. Our previous study reported that NF‑κB enhanced the secretion of interleukin (IL)‑8 and vascular endothelial growth factor (VEGF), thereby inducing angiogenesis in PaCa cell lines. In the present study, it was examined whether escin inhibited angiogenesis by blocking NF‑κB activation in PaCa. It was initially confirmed that escin, at concentrations >10 µM, significantly inhibited the proliferation of several PaCa cell lines. Next, using immunocytochemical staining, it was found that escin inhibited the nuclear translocation of NF‑κB. Furthermore, ELISA confirmed that NF‑κB activity in the escin‑treated PaCa cells was significantly inhibited and reverse transcription‑quantitative PCR showed that the mRNA expression levels of tumor necrosis factor‑α‑induced IL‑8 and VEGF were significantly suppressed following escin treatment in the PaCa cell lines. ELISA also showed that escin decreased the secretion of IL‑8 and VEGF from the PaCa cells. Furthermore, tube formation in immortalized human endothelial cells was inhibited following incubation with the supernatants from escin‑treated PaCa cells. These results indicated that escin inhibited angiogenesis by reducing the secretion of IL‑8 and VEGF by blocking NF‑κB activity in PaCa. In conclusion, escin could be used as a novel molecular therapy for PaCa.
View Figures
View References

Related Articles

Journal Cover

May-2021
Volume 45 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Omi K, Matsuo Y, Ueda G, Aoyama Y, Kato T, Hayashi Y, Imafuji H, Saito K, Tsuboi K, Morimoto M, Morimoto M, et al: Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines. Oncol Rep 45: 55, 2021.
APA
Omi, K., Matsuo, Y., Ueda, G., Aoyama, Y., Kato, T., Hayashi, Y. ... Takiguchi, S. (2021). Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines. Oncology Reports, 45, 55. https://doi.org/10.3892/or.2021.8006
MLA
Omi, K., Matsuo, Y., Ueda, G., Aoyama, Y., Kato, T., Hayashi, Y., Imafuji, H., Saito, K., Tsuboi, K., Morimoto, M., Ogawa, R., Takahashi, H., Takiguchi, S."Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines". Oncology Reports 45.5 (2021): 55.
Chicago
Omi, K., Matsuo, Y., Ueda, G., Aoyama, Y., Kato, T., Hayashi, Y., Imafuji, H., Saito, K., Tsuboi, K., Morimoto, M., Ogawa, R., Takahashi, H., Takiguchi, S."Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines". Oncology Reports 45, no. 5 (2021): 55. https://doi.org/10.3892/or.2021.8006